O2h to provide ADME services to Sentinel Oncology under new extended contract

Executives from Sentinel Oncology Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) to extend the number of FTEs working for Sentinel Oncology. Under this new contract, O2h will also provide ADME services to Sentinel Oncology.

Bob Boyle, CEO of Sentinel Oncology said that he appreciated O2h's continual support and it being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.

COO of Sentinel Oncology, Stuart Travers said "ADME support added onto the chemistry FTEs provides us with a seamless and quick way of gathering data for our on-going projects. We look forward to working with O2h and of taking advantage of its expanding ADME portfolio."

Sunil Shah, CEO, O2h "We have an incredibly good relationship with Sentinel Oncology and are happy to continue supporting their virtual model with not just our chemistry but also ADME. O2h ADME services are being expanded with current purchase of high-spec specialised instruments and support of our long-standing clients is appreciated."